annual cash & cash equivalents:
$276.77M+$123.48M(+80.55%)Summary
- As of today (June 30, 2025), PCRX annual cash & cash equivalents is $276.77 million, with the most recent change of +$123.48 million (+80.55%) on December 31, 2024.
- During the last 3 years, PCRX annual cash & cash equivalents has fallen by -$308.80 million (-52.73%).
- PCRX annual cash & cash equivalents is now -52.73% below its all-time high of $585.58 million, reached on December 31, 2021.
Performance
PCRX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$283.61M+$6.84M(+2.47%)Summary
- As of today (June 30, 2025), PCRX quarterly cash & cash equivalents is $283.61 million, with the most recent change of +$6.84 million (+2.47%) on March 31, 2025.
- Over the past year, PCRX quarterly cash & cash equivalents has increased by +$99.56 million (+54.09%).
- PCRX quarterly cash & cash equivalents is now -51.57% below its all-time high of $585.58 million, reached on December 31, 2021.
Performance
PCRX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PCRX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +80.5% | +54.1% |
| 3 y3 years | -52.7% | +25.1% |
| 5 y5 years | +253.8% | +419.5% |
PCRX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -52.7% | +165.8% | at high | +697.9% |
| 5 y | 5-year | -52.7% | +253.8% | -51.6% | +697.9% |
| alltime | all time | -52.7% | +3810.9% | -51.6% | +8283.4% |
PCRX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $283.61M(+2.5%) |
| Dec 2024 | $276.77M(+80.5%) | $276.77M(+12.5%) |
| Sep 2024 | - | $245.97M(-0.4%) |
| Jun 2024 | - | $247.05M(+34.2%) |
| Mar 2024 | - | $184.05M(+20.1%) |
| Dec 2023 | $153.30M(+47.2%) | $153.30M(+54.7%) |
| Sep 2023 | - | $99.12M(+14.2%) |
| Jun 2023 | - | $86.81M(+144.2%) |
| Mar 2023 | - | $35.55M(-65.9%) |
| Dec 2022 | $104.14M(-82.2%) | $104.14M(-4.8%) |
| Sep 2022 | - | $109.42M(-10.4%) |
| Jun 2022 | - | $122.06M(-46.2%) |
| Mar 2022 | - | $226.75M(-61.3%) |
| Dec 2021 | $585.58M(+485.8%) | $585.58M(+336.9%) |
| Sep 2021 | - | $134.04M(+26.7%) |
| Jun 2021 | - | $105.77M(+58.6%) |
| Mar 2021 | - | $66.70M(-33.3%) |
| Dec 2020 | $99.96M(+27.8%) | $99.96M(-20.2%) |
| Sep 2020 | - | $125.24M(+59.4%) |
| Jun 2020 | - | $78.55M(+43.9%) |
| Mar 2020 | - | $54.59M(-30.2%) |
| Dec 2019 | $78.23M(-41.0%) | $78.23M(-8.1%) |
| Sep 2019 | - | $85.14M(+42.5%) |
| Jun 2019 | - | $59.74M(-72.2%) |
| Mar 2019 | - | $215.04M(+62.3%) |
| Dec 2018 | $132.53M(+144.8%) | $132.53M(-42.6%) |
| Sep 2018 | - | $230.94M(+97.6%) |
| Jun 2018 | - | $116.87M(+181.2%) |
| Mar 2018 | - | $41.56M(-23.2%) |
| Dec 2017 | $54.13M | $54.13M(+106.5%) |
| Sep 2017 | - | $26.22M(-51.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $53.81M(-50.6%) |
| Mar 2017 | - | $108.97M(+203.2%) |
| Dec 2016 | $35.94M(-36.9%) | $35.94M(+47.1%) |
| Sep 2016 | - | $24.44M(-3.4%) |
| Jun 2016 | - | $25.31M(-27.7%) |
| Mar 2016 | - | $35.03M(-38.5%) |
| Dec 2015 | $56.98M(+51.9%) | $56.98M(+86.7%) |
| Sep 2015 | - | $30.52M(-6.7%) |
| Jun 2015 | - | $32.72M(-20.0%) |
| Mar 2015 | - | $40.90M(+9.0%) |
| Dec 2014 | $37.52M(+199.8%) | $37.52M(+111.3%) |
| Sep 2014 | - | $17.76M(-83.6%) |
| Jun 2014 | - | $108.20M(+476.7%) |
| Mar 2014 | - | $18.76M(+49.9%) |
| Dec 2013 | $12.52M(+23.6%) | $12.52M(+269.9%) |
| Sep 2013 | - | $3.38M(-60.8%) |
| Jun 2013 | - | $8.63M(-67.2%) |
| Mar 2013 | - | $26.27M(+159.5%) |
| Dec 2012 | $10.13M(-78.1%) | $10.13M(+16.3%) |
| Sep 2012 | - | $8.71M(-59.4%) |
| Jun 2012 | - | $21.45M(-14.9%) |
| Mar 2012 | - | $25.21M(-45.4%) |
| Dec 2011 | $46.17M(+76.7%) | $46.17M(+181.5%) |
| Sep 2011 | - | $16.40M(-40.2%) |
| Jun 2011 | - | $27.45M(-53.7%) |
| Mar 2011 | - | $59.33M(+127.0%) |
| Dec 2010 | $26.13M(+269.3%) | $26.13M(+88.7%) |
| Sep 2010 | - | $13.85M(+12.1%) |
| Jun 2010 | - | $12.35M(+74.6%) |
| Dec 2009 | $7.08M(-42.9%) | $7.08M |
| Dec 2008 | $12.39M | - |
FAQ
- What is Pacira BioSciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pacira BioSciences?
- What is Pacira BioSciences annual cash & cash equivalents year-on-year change?
- What is Pacira BioSciences quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Pacira BioSciences?
- What is Pacira BioSciences quarterly cash & cash equivalents year-on-year change?
What is Pacira BioSciences annual cash & cash equivalents?
The current annual cash & cash equivalents of PCRX is $276.77M
What is the all time high annual cash & cash equivalents for Pacira BioSciences?
Pacira BioSciences all-time high annual cash & cash equivalents is $585.58M
What is Pacira BioSciences annual cash & cash equivalents year-on-year change?
Over the past year, PCRX annual cash & cash equivalents has changed by +$123.48M (+80.55%)
What is Pacira BioSciences quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of PCRX is $283.61M
What is the all time high quarterly cash & cash equivalents for Pacira BioSciences?
Pacira BioSciences all-time high quarterly cash & cash equivalents is $585.58M
What is Pacira BioSciences quarterly cash & cash equivalents year-on-year change?
Over the past year, PCRX quarterly cash & cash equivalents has changed by +$99.56M (+54.09%)